Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Large Volume Increase - Still a Buy?

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR saw a significant trading volume increase of 456%, with approximately 610,343 shares changing hands in one day.
• The company's latest earnings report revealed an EPS of $0.16, surpassing analysts' expectations of $0.14, although revenue of $672.90 million fell short of estimates.
• Shionogi specializes in developing and distributing pharmaceuticals, including treatments for HIV, COVID-19, and antibiotics.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 610,343 shares changed hands during trading, an increase of 456% from the previous session's volume of 109,755 shares.The stock last traded at $8.86 and had previously closed at $8.74.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The company has a market cap of $15.02 billion, a P/E ratio of 14.77, a PEG ratio of 1.98 and a beta of 0.20. The company has a quick ratio of 6.13, a current ratio of 6.63 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $8.51 and a 200-day moving average price of $7.97.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The company had revenue of $672.90 million during the quarter, compared to the consensus estimate of $719.55 million. Equities analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.